Category - Developments

Developments

Canopy Growth to purchase cannabis extract from MediPharm Labs

Canopy Growth (TSX:WEED; NYSE:CGC) has entered an 18-month strategic supply agreement with a unit of MediPharm Labs (TSXV:LABS) to purchase up to 900 kg of cannabis extract. Canopy Growth has committed to purchase a...

November 29, 2018

Developments

Health Canada approves Opsens dPR in coronary heart disease

Health Canada approved Opsens’ (TSX:OPS; OTCQX:OPSSF) diastolic pressure ratio (dPR) proprietary resting index, which measures intracoronary pressure and establishes a diagnosis with the heart at rest to guide treatment...

November 28, 2018

Developments

Canopy Growth, Battelle to collaborate in cannabis research

Canopy Growth (TSX:WEED; NYSE: CGC) has completed four product transfers of legal cannabis to Ohio-based Battelle, the world’s largest non-profit research and development organization, to support medical research...

November 27, 2018

Developments

IntelGenx begins patient dosing in VersaFilm Phase 2a AD study

IntelGenx (TSXV:IGX; OTCQX:IGXT) began patient dosing in the Phase 2a study of Montelukast VersaFilm in patients with mild-to-moderate Alzheimer’s disease (AD). The True North Clinical Research site in Kentville, Nova...

November 27, 2018

Developments

Leerink starts coverage of 10 biopharma and generic stocks

Leerink initiated coverage of 10 biopharma and generic stocks, saying the sector is rich with companies developing drugs with the aim to treat and/or definitively cure conditions ranging from rare, severe inherited...

November 27, 2018

Developments

Interface Biologics preparing Phase 2 intravitreal implant study after FDA meeting

Following a successful pre-IND meeting with FDA, closely-held Interface Biologics (IBI) is preparing to initiate a Phase 2 trial with its dexamethasone intravitreal implantin patients with diabetic macular edema. The...

November 27, 2018

Developments

Canopy Growth completes acquisition of ebbu assets

Canopy Growth (TSX:WEED; NYSE:CGC) completed the acquisition of the assets of ebbu, a leader in hemp research and innovation, for $25-million and 6,221,210 common shares. Under the accord, Canopy would pay up to an...

November 26, 2018

Developments

Lobo Genetics going public in RTO of Cassowary Capital

Closely-held Lobo Genetics entered into a non-binding letter of intent with Cassowary Capital (TSXV:BIRD) that will result in a reverse takeover of Cassowary by Lobo. Cassowary is a capital pool company on the TSX...

November 22, 2018

Developments

FDA accepts IntelGenx NDA resubmission for RIZAPORT

The FDA accepted IntelGenx’s (TSXV:IGX; OTCQX: IGXT) 505(b)(2) NDA resubmission of RIZAPORT oral soluble film 10 mg for the treatment of acute migraines. The FDA also assigned a Prescription Drug User Fee Act (PDUFA)...

November 20, 2018

Developments

IntelGenx gains media attention for VersaFilm delivery of cannabis

The Canada Pot Talks radio show has interviewed Horst Zerbe, president and CEO of IntelGenx (TSXV:IGX; OTCQX:IGXT), about its partnership with Tilray (NASDAQ:TLRY) to co-develop and commercializean IntelGenx VersaFilm...

November 20, 2018

Category - Developments

Subscribe